A novel framework for chimeric transcript detection based on accurate gene fusion model

Next generation sequencing plays a key role in the detection of structural variations. Chimeric transcripts are relevant examples of such variations, as they are involved in several diseases. In this work, we propose an effective methodology for the detection of fused transcripts in RNA-Seq paired-end data. The proposed methodology is based on an accurate fusion model implemented by a set of filters reducing the impact of artifacts. Moreover, the methodology accounts for transcripts consistently expressing in the sample under study even if they are not annotated. The effectiveness of the proposed solution has been experimentally validated on of Chronic Myelogenous Leukemia (CML) samples, providing both the genes involved in the fusion and the exact chimeric sequence. \ua9 2011 IEEE

FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data

We have developed FusionSeq to identify fusion transcripts from paired-end RNA-sequencing. FusionSeq includes filters to remove spurious candidate fusions with artifacts, such as misalignment or random pairing of transcript fragments, and it ranks candidates according to several statistics. It also has a module to identify exact sequences at breakpoint junctions. FusionSeq detected known and novel fusions in a specially sequenced calibration data set, including eight cancers with and without known rearrangements

Highly Sensitive and Specific Method for Detection of Clinically Relevant Fusion Genes across Cancer

Gene fusions are strong driver mutations in cancer and can be used as a diagnostic tool to predict different tumour phenotypes and treatments. Several fusion detection algorithms for RNA-Seq data have been developed, but all of them report a consistently high number of false positive events. Therefore, new methods are crucial to accurately identify potential fusions that may be key drivers of oncogenesis. We developed Fusion Validator, a new filtering tool able to discriminate false positive fusion transcripts from real fusions and significantly reduce the number of candidates to assess for experimental validation. Fusion Validator perform a local realignment of reads on each fusion transcript sequence and tries to close the gap around the fusion breakpoint using both a de novo assembly and a seed-extend algorithm. If the algorithm fails to reconstruct the fusion transcript around the breakpoint, the fusion is considered as false positive and is discarded. Additional filtering steps are used to remove fusions with breakpoints mapping on low complexity or homologous regions and to find correct fusion partners for promiscuous gene fusion events. A final ranking score based on fusion annotation is created for each validated event to help distinguish real driver fusions from passengers one. We tested Fusion Validator on simulated datasets of different coverage, read length and breakpoint positions, and on four published breast cancer Cell Lines, highlighting the massive increase in sensisitivity, precision and specificity of our algorithm, in comparison to other fusion-detection software. Using this tool, we successfully detected 97.95% of PCR-validated kinase recurrent fusions in 190 pan cancer samples, removing approximately 79.95% of false positives. Particularly in haematological disorders and childhood sarcomas, gene fusions are critical as diagnostic and prognostic factors. Therefore, development of this novel tool to increase the efficiency of detecting driver fusions is critical in disease detection and treatment

Development and Application of Next-Generation Sequencing Methods to Profile Cellular Translational Dynamics

The transmission of genetic information from the transcription of DNA to RNA and the subsequent translation of RNA into protein is often abstracted into a linear process. However, as methods and technologies to measure the genomic, transcriptomic, and proteomic content of cells have advanced, so too has our understanding that the transmission of genetic information does not always flow in a lossless manner. For instance, changes observed in messenger RNA (mRNA) abundance are not always retained at the proteomic level. Indeed, a diverse array of mechanisms have been identified that exert regulatory control over this transmission of information. Next-generation short read sequencing has driven many of these insights and provided increasingly nuanced understanding of these regulatory mechanisms. However, the continued development and application of sequencing methodologies and analytics are required to properly contextualize many of these insights on a more global scale. Ribosome profiling is one such recent advancement which enriches for ribosome-protected fragments of mRNA; sequencing and analysis of these ribosome-protected mRNA fragments enables profiling of the translational content of a sample. The aim of this dissertation is to address the need for the development and application of statistical and analytical algorithms to profile the regulatory factors that contribute to the translational dynamics in cells. In the first chapter, I survey the development and application of next-generation sequencing methods for the profiling and computational analysis of translation and translational dynamics. In the second chapter of this thesis, I present SPECtre, a software package that identifies regions of active translation through measurement of the translational engagement of ribosomes over a transcript. SPECtre achieves high sensitivity and specificity in its classification of regions undergoing translation by leveraging the codon-dependent elongation of peptides; this tri-nucleotide periodicity is evident in the alignment of ribosome profiling sequence reads to a reference transcriptome. SPECtre classifies actively translated transcripts according to their coherence in read coverage over a region to an optimal tri-nucleotide signal. In the third chapter, I describe the application of SPECtre to identify the translation of upstream-initiated open-reading frames that may regulate differentiation in a neuron-like cell model. uORFs are transcripts that result from the initiation of translation from AUG, and under certain biological constraints, from non-AUG sequences localized in the 5’ untranslated regions of annotated protein-coding genes. Subsets of these uORFs have been implicated in the regulation of their downstream protein-coding genes in yeast, mice and humans. In this chapter, I provide further evidence for this regulation as well as the spatial context for the functional consequences of uORF translation on downstream protein-coding genes in a neuron-like cell line model of differentiation. Finally, in the fourth chapter, I outline a strategy using our coherence-based translational scoring algorithm to profile ribosomal engagement over chimeric gene fusion breakpoints in prostate cancer. Here, known breakpoints from current annotation databases are integrated with novel junctions nominated by existing whole genome and transcriptomic gene fusion detection algorithms, and the translational profile over these chimeric junctions using SPECtre is measured. This provides an additional layer of translational evidence to known and novel gene fusion breakpoints in prostate cancer. Ongoing development of a database and visualization platform based on these results will enable integrative insights into the transcriptional and translational topology of these breakpoints.PHDBioinformaticsUniversity of Michigan, Horace H. Rackham School of Graduate Studieshttps://deepblue.lib.umich.edu/bitstream/2027.42/144106/1/stonyc_1.pd

FuGePrior: A novel gene fusion prioritization algorithm based on accurate fusion structure analysis in cancer RNA-seq samples

Abstract Background Latest Next Generation Sequencing technologies opened the way to a novel era of genomic studies, allowing to gain novel insights into multifactorial pathologies as cancer. In particular gene fusion detection and comprehension have been deeply enhanced by these methods. However, state of the art algorithms for gene fusion identification are still challenging. Indeed, they identify huge amounts of poorly overlapping candidates and all the reported fusions should be considered for in lab validation clearly overwhelming wet lab capabilities. Results In this work we propose a novel methodological approach and tool named FuGePrior for the prioritization of gene fusions from paired-end RNA-Seq data. The proposed pipeline combines state of the art tools for chimeric transcript discovery and prioritization, a series of filtering and processing steps designed by considering modern literature on gene fusions and an analysis on functional reliability of gene fusion structure. Conclusions FuGePrior performance has been assessed on two publicly available paired-end RNA-Seq datasets: The first by Edgren and colleagues includes four breast cancer cell lines and a normal breast sample, whereas the second by Ren and colleagues comprises fourteen primary prostate cancer samples and their paired normal counterparts. FuGePrior results accounted for a reduction in the number of fusions output of chimeric transcript discovery tools that ranges from 65 to 75% depending on the considered breast cancer cell line and from 37 to 65% according to the prostate cancer sample under examination. Furthermore, since both datasets come with a partial validation we were able to assess the performance of FuGePrior in correctly prioritizing real gene fusions. Specifically, 25 out of 26 validated fusions in breast cancer dataset have been correctly labelled as reliable and biologically significant. Similarly, 2 out of 5 validated fusions in prostate dataset have been recognized as priority by FuGePrior tool

Discovering cancer-associated transcripts by RNA sequencing

High-throughput sequencing of poly-adenylated RNA (RNA-Seq) in human cancers shows remarkable potential to identify uncharacterized aspects of tumor biology, including gene fusions with therapeutic significance and disease markers such as long non-coding RNA (lncRNA) species. However, the analysis of RNA-Seq data places unprecedented demands upon computational infrastructures and algorithms, requiring novel bioinformatics approaches. To meet these demands, we present two new open-source software packages - ChimeraScan and AssemblyLine - designed to detect gene fusion events and novel lncRNAs, respectively. RNA-Seq studies utilizing ChimeraScan led to discoveries of new families of recurrent gene fusions in breast cancers and solitary fibrous tumors. Further, ChimeraScan was one of the key components of the repertoire of computational tools utilized in data analysis for MI-ONCOSEQ, a clinical sequencing initiative to identify potentially informative and actionable mutations in cancer patients’ tumors. AssemblyLine, by contrast, reassembles RNA sequencing data into full-length transcripts ab initio. In head-to-head analyses AssemblyLine compared favorably to existing ab initio approaches and unveiled abundant novel lncRNAs, including antisense and intronic lncRNAs disregarded by previous studies. Moreover, we used AssemblyLine to define the prostate cancer transcriptome from a large patient cohort and discovered myriad lncRNAs, including 121 prostate cancer-associated transcripts (PCATs) that could potentially serve as novel disease markers. Functional studies of two PCATs - PCAT-1 and SChLAP1 - revealed cancer-promoting roles for these lncRNAs. PCAT1, a lncRNA expressed from chromosome 8q24, promotes cell proliferation and represses the tumor suppressor BRCA2. SChLAP1, located in a chromosome 2q31 ‘gene desert’, independently predicts poor patient outcomes, including metastasis and cancer-specific mortality. Mechanistically, SChLAP1 antagonizes the genome-wide localization and regulatory functions of the SWI/SNF chromatin-modifying complex. Collectively, this work demonstrates the utility of ChimeraScan and AssemblyLine as open-source bioinformatics tools. Our applications of ChimeraScan and AssemblyLine led to the discovery of new classes of recurrent and clinically informative gene fusions, and established a prominent role for lncRNAs in coordinating aggressive prostate cancer, respectively. We expect that the methods and findings described herein will establish a precedent for RNA-Seq-based studies in cancer biology and assist the research community at large in making similar discoveries.PHDBioinformaticsUniversity of Michigan, Horace H. Rackham School of Graduate Studieshttp://deepblue.lib.umich.edu/bitstream/2027.42/120814/1/mkiyer_1.pd

Discovering chimeric transcripts in paired-end RNA-seq data by using EricScript

Abstract Motivation: The discovery of novel gene fusions can lead to a better comprehension of cancer progression and development. The emergence of deep sequencing of trancriptome, known as RNA-seq, has opened many opportunities for the identification of this class of genomic alterations, leading to the discovery of novel chimeric transcripts in melanomas, breast cancers and lymphomas. Nowadays, few computational approaches have been developed for the detection of chimeric transcripts. Although all of these computational methods show good sensitivity, much work remains to reduce the huge number of false-positive calls that arises from this analysis. Results: We proposed a novel computational framework, named chimEric tranScript detection algorithm (EricScript), for the identification of gene fusion products in paired-end RNA-seq data. Our simulation study on synthetic data demonstrates that EricScript enables to achieve higher sensitivity and specificity than existing methods with noticeably lower running times. We also applied our method to publicly available RNA-seq tumour datasets, and we showed its capability in rediscovering known gene fusions. Availability: The EricScript package is freely available under GPL v3 license at http://ericscript.sourceforge.net. Contact: [email protected] Supplementary information: Supplementary data are available at Bioinformatics online

Long-read transcriptome sequencing analysis with IsoTools

Long-read transcriptome sequencing (LRTS) holds the promise to boost our understanding of alternative splicing. Recent advances in accuracy and throughput have diminished the major limitations and enabled the direct quantification of isoforms. Considering the complexity of the data and the broad range of potential applications, it is clear that highly flexible, accurate analysis tools are crucial. Here, we present IsoTools, a comprehensive Python-based analysis package, for the improvement of alternative and differential splicing analysis. Iso-Tools provides a comprehensive data structure that integrates genomic information from LRTS transcripts together with the reference annotation, and enables broad functionality to quality control, visualize and analyze the data. Additionally, we implemented a graph-based method for the identification of alternative splicing events and a statistical approach based on the beta binomial distribution for the detection of differential events. To demonstrate our methods, we generated PacBio Iso-Seq data of human hepatocytes treated with the HDAC inhibitor valproic acid, a compound known to induce widespread transcriptional changes. Contrasted with short read RNA-Seq of the same samples, this analysis shows that LRTS provides valuable additional insights for a better understanding of alternative splicing, in particular with respect to complex novel and differential splicing events. IsoTools is made available for the community along with extensive documentation at https://github.com/MatthiasLienhard/isotools